Teva to launch production of Copaxone in Russia

17 October 2016

Israeli generic pharma behemoth Teva Pharmaceutical Industries (NYSE: TEVA) will establish production of its injectable drugs in Russia, at the facilities of the local Nanolek enterprise. It is planned that production will be established in the Kirov region, according to The Pharma Letter’s local correspondent.

At the initial stage, the company will focus on the production of Copaxone (glatiramer acetate), its blockbuster drug for the treatment of multiple sclerosis. The first shipments are scheduled for the second half of 2017, but production will reach its full cycle in the fourth quarter of 2018.

The drug is purchased by the Russian Health Ministry under the "Seven nosologies" program, which is a state procurement program that involves purchases of the most expensive drugs for state needs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK